July 8, 2020
June 30, 2020
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
May 20, 2020
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
April 27, 2020
Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
April 25, 2020
US FDA Allows Trial to Proceed for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)
April 16, 2020
Retrotope Initiates Project to Test RT001 in an Animal Model of Lung Damage to protect against COVID-19 impact
February 20, 2020
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP).
January 9, 2020
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)
October 3, 2019
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
September 17, 2019